VirTra GAAP EPS of $0.19 beats by $0.25, revenue of $7.6M beats by $3.21M

VirTra reported Q3 GAAP EPS of $0.19, beating estimates by $0.25, with revenue of $7.6M, up 43.4% year-over-year and exceeding expectations by $3.21M. The company also secured a five-year contract with U.S. Customs and Border Protection.

Original reporting
Published Nov 12, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VTSI
Bullish
high confidence
Mentioned
$VTSI
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$VTSIBullishMed
01

Why it matters

The earnings surprise could attract short‑term buying interest and trigger analyst upgrades.

02

Market read

Micro‑cap earnings beat with strong revenue growth offers a modest trading opportunity.

03

What to watch

Potential volatility from reliance on government contracts and limited operating history.

Relevance 6/10Novelty 7/10Timing: after-hours

Background

VirTra is a provider of simulation‑based training and safety solutions for law‑enforcement and military customers.

Company-level read

Ticker impact

$VTSIBullishHigh confidence
Context

VirTra reported Q3 GAAP EPS of $0.19, beating expectations by $0.25 and revenue of $7.6M, up 43.4% YoY, beating by $3.21M.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

Both EPS and revenue exceeded expectations, a rare positive surprise for this micro‑cap.

Market effects

Positive earnings may lift other public safety and training‑service providers.

Limited to U.S. small‑cap segment.

Low global relevance.

Counterpoint

The beat may be temporary if the contract pipeline does not sustain growth.

Key entities

  • VirTra, Inc.

    Public safety training technology firm.

Related articles

$VTSIMed

VirTra Reports Third Quarter and Nine Months 2026 Financial Results

VirTra, Inc (VTSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VirTra Reports Third Quarter and Nine Months 2026 Financial Results CHANDLER, Ariz. — November 12, 2026 — VirTra, Inc . (Nasdaq: VTSI) ( “ VirTra ” or the “ Company ” ), a global provider of judgmental use-of-force and firearms training simulators, reported results f

$VTSIMed

VirTra Reports Second Quarter and Six Months 2026 Financial Results

VirTra, Inc (VTSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VirTra Reports Second Quarter and Six Months 2026 Financial Results CHANDLER, Ariz. — August 13, 2026 — VirTra, Inc . (Nasdaq: VTSI) ( “ VirTra ” or the “ Company ” ), a global provider of judgmental use-of-force and firearms training simulators, reported results for

$VTSIMedAI 8/10

VirTra (NASDAQ:VTSI) Trading Down 2.9% – What’s Next?

VirTra (NASDAQ:VTSI) shares fell 2.9% to $3.33 on Monday, after trading as low as $3.22; the session volume of 107,453 shares was up 45% versus the average. Research firms cited mixed views: Lake Street cut its target to $5.00 (buy), while Wall Street Zen and Zacks cut to sell/strong sell. In its May 11 quarter, VirTra reported EPS of -$0.12 and revenue of $3.47M.

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.